Navigation Links
Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
Date:1/9/2014

MOUNTAIN VIEW, Calif., Jan. 9, 2014 /PRNewswire/ -- Xlumena, Inc., a leader in advanced endoscopic devices, today announced the first US commercial use of its AXIOS Stent and Delivery System (AXIOS) at California Pacific Medical Center (CPMC) in San Francisco.  The recent FDA clearance of AXIOS represents a significant breakthrough in the treatment of patients with pancreatic pseudocysts and fluid collections.

There are more than 90,000 cases of pseudocysts and pancreatic fluid collections in the US each year and the global market is estimated to be greater than $200 million annually.  Prior to the FDA clearance of AXIOS last month, physicians had no "on-label" options for treating these conditions.  According to Christy Foreman, director of the Office of Device Evaluation at the FDA, "the AXIOS Stent provides a new option for physicians to effectively treat pseudocysts."

AXIOS is the first stent specifically designed for treatment of a pancreatic pseudocyst or fluid collection.   Its design allows for rapid drainage of these fluid collections, which are often filled with thick, infected or necrotic content.

"I'm delighted that we now have an anastomotic stent that was designed specifically for drainage of pancreatic fluid collections," said Dr. Kenneth Binmoeller, Founder and Chief Medical Officer of Xlumena.   Following FDA clearance of AXIOS, Dr. Binmoeller performed the first drainage of a pancreatic pseudocyst with AXIOS at CPMC.  "After AXIOS placement, we were able to clear out debris from the cyst with the endoscope, which led to immediate improvement of the patient's clinical course."  

Having just closed a $25M Series C financing, Xlumena is expanding to meet the demand for AXIOS, initiating a targeted launch in selected centers of excellence across the US. AXIOS is the first in a family of devices that Xlumena plans to bring to the US market to address significant clinical needs in the field of interventional endoscopy.  Already CE marked and used in rapidly growing numbers is the next-generation HOT AXIOS, which incorporates cautery into the delivery of the AXIOS stent and is currently used in Europe for the treatment of pancreatic pseudocysts, acute cholecystitis and biliary obstruction.

CAUTION: The HOT AXIOS and AXIOS devices for the gallbladder and bile duct have CE mark designation in Europe. They are not available for sale in the United States. 

For more information about the AXIOS Stent and Delivery System, please visit www.xlumena.com.

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced, image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

Video with caption: "AXIOS Stent and Delivery System Procedure Animation". Video available at: http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-SF43594-20140109-1.mp4

Contact:
Joni Cronin
650-961-9900
jcronin@xlumena.com


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
2. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
3. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
4. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
5. Endo Announces Divestiture Of HealthTronics
6. The MED Group Announces Agreement with Golden Technologies
7. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Navigating Cancer Announces Milestones Related to Patient Education Program
10. TRICAST Announces Patent-Pending Technology for Real-Time Health Data Analysis
11. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... DANVILLE, Pa. , Dec. 8, 2016  A ... physicians reports that the use of opioid therapy to ... actually increase the likelihood of more harmful consequences, including ... Davis , M.D., and Zankhana Mehta , M.D., ... current research on chronic opioid therapy. The study was ...
(Date:12/8/2016)... , December 8, 2016 Information products and ... metrics in Scopus , the world,s largest abstract and ... to comprehensive metrics for journals from over 5,000 publishers. The new ... journals to subscribe to and when to adjust a journal,s editorial ... , , ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Jefferson County, is announcing the launch ... Shelter in Birmingham. , The number of homeless women and children in Birmingham ...
Breaking Medicine News(10 mins):